|
We
have published instructions |
We have published instructions for the synthesis of 52 pterins on the
website of Schircks Laboratories.
These instructions do not meet the
requirements for publication in scientific journals and these
instructions are not written in correct English, but with these detailed
instructions a skilled chemist can prepare the substance described.
These instructions may be used free of charge, but copyright
applies. |
We
only sell
October 2020 |
Schircks Laboratories now only has two staff
members, Ms Zingg and myself.
I am 74 years old and no longer produces any
substances.
We still have sufficient amounts of many
substances in storage to supply you. Retests are carried out regularly
with all substances.
Ms
Zingg will reach her pension age
spring 2021. However, she will continue to manage the sale of substances of
Schircks Laboratories.
|
|
New
address |
Schircks Laboratories, Postfach, 8494 Bauma, Switzerland |
|
New
email address
|
The company Dotster has suspended our domain name. From now one you can contact us under the following email
address:
labschircks@gmail.com
|
|
New
Compound February
2014
|
Please note that the compound product number
16.500 7-Hydroxymethotrexate is again available.
|
|
Products
listed as an Excel file
June
2013
|
Our new price list can be found on our
website presented alphabetically or numerically as pdf files with links
to our data sheets or numerically as an Excel file with CAS numbers.
|
|
We
have to
adjust Pteridine
prices
April
2013
|
We have to adjust Pteridine prices. The
prices will automatically change April 1, 2013.
|
|
Tetrahydrobiopterin
tablets are sold out
October 2011
|
Tetrahydrobiopterin tablets
10 mg and 50 mg are sold out. Unfortunately there is nothing we can do to change this
dissatisfactory situation.
Although Schircks Laboratories sold
tetrahydrobiopterin tablets on a compassionate use basis over 25 years,
we did not have a marketing authorization. Orphan drug law only came
into effect in 2002. Biomarin and Merck Serono could take advantage of
these new laws and because they had adequate financial assets to support
the clinical trials. Schircks Laboratories had no chance to compete.
Biomarin and Merck Serono performed all clinical trials required to get
approval for a new drug. They received marketing authorizations as an
orphan drug in the USA, Japan and Europe. As a result no other company
can legally sell medication containing tetrahydrobiopterin in the USA,
Japan and Europe over the next 10 years.
Although we
applied for a marketing authorization in Switzerland
and had not much missing to receive approval here, the loss of the US,
Japanese and European markets to Biomarin and Merck Serono made it
impossible to remain viable.
We
never and in no way whatsoever cooperated with Biomarin and Merck Serono.
We would like to thank you for the pleasant
co-operation over the years.
|
|
Diminishing
stocks
April 2010
|
We
now only have a limited stock of Tetrahydrobiopterin tablets remaining.
We are only accepting orders from existing customers from low income
developing countries until our stock is depleted. We cannot accept
orders from any new patients from any country. Taking into account that
tablets from Merck Serono will be about three times more expensive
than our tablets, we urge you not to start
treatment of new patients with Tetrahydrobiopterin tablets until
the financial side of the treatment is examined. Otherwise the relief of
the strain of the diet will be replaced with bigger financial strain.
|
|
Biomarin
and Merck Serono
January 2010
|
Biomarin
and Merck Serono have taken over the Tetrahydrobiopterin tablet market.
We have had to cease production of tetrahydrobiopterin. We
now only have a limited stock of
Tetrahydrobiopterin tablets remaining. We can only accept orders
from low income developing countries until our stock is depleted.
Unfortunately there is nothing we can do to change this situation. We
would like to thank you for the pleasant cooperation through many years.
Please note that the active substance (Sapropterin dihydrochloride) in
Biomarin/Merck Serono`s tablets Kuvan is the same as that in Schircks
Laboratories Tetrahydrobiopterin tablets. Sapropterin dihydrochloride is
another name for Tetrahydrobiopterin (BH4). Please contact Biomarin/Merck
Serono to ensure a continuous supply of tablets.
|
|
Merck
Serono expands Kuvan market
November 2009 |
In
November 2009 Merck
Serono (www.merckserono.com) took over the market in Great Britain,
France, Germany, Spain, Austria, Greek, Denmark, Hungary, Italy and Netherlands.
|
|
Tetrahydrobiopterin
tablets – future suppliers
December 2008 |
Doctors,
clinics, health authorities and ethic commissions depended on the supply
of tetrahydrobiopterin provided on a compassionate use / named patient
basis from Schircks Laboratories over the last 28 years. Because
tetrahydrobiopterin deficiency is a very rare disorder it was impossible
to perform organized clinical trials.
In
1999 it was found that a larger group of PKU/HPA patients also responded
to treatment with Schircks Laboratories tetrahydrobiopterin. Clinical
trials were organized and data was collected by Biomarin and after FDA
approval in 2007, they
started to supply the US Market 2008. Tetrahydrobiopterin is an
orphan drug. Special regulations apply to the sale of this product.
Merck Serono received marketing authorization for the sale of
tetrahyrobiopterin (sapropterin) in Europe December 2, 2008. Schircks
Laboratories is legally obliged to discontinue the sale of
tetrahydrobiopterin to Europe as soon as Merck Serono brings their
product Kuvan on the market. We will keep you informed of changes as
they come about.
Biomarin
and Merck Serono will only sell unscored 100 mg sapropterin tablets.
Because
there have been extensive clinical trials for their product on large
groups of patients, the cost of the tablets is expected to be higher
than those supplied by Schircks Laboratories.
However,
it is expected that health funds are more likely to cover a
product, which has a marketing authorization.
We will keep you informed of changes on
our website. For updates, please check this website regularly.
|